1% Lidocaine HCL Injection By Hospira: Recall - Presence Of Dark Particulate

May result in local inflammation, phlebitis, and/or low-level allergic response, and could block administration of the drug to the patient, causing a delay in therapy.

Source: FDA MedWatch - October 5, 2013 Category: American Health Source Type: news